China SXT Pharmaceuticals makes generic and specialty drugs in China, and the data we have shows a business in serious retreat: revenue down 43.9%, operating margin at -153.3%, and ROE at -27.5%. The 21.9% gross margin means the product line still earns something on each unit sold, but it is far from covering overhead at this scale. With a market capitalisation of about $713 thousand, no index membership, and a P/E that is not meaningful given the losses, the name sits outside the universe where a concentrated long-only book would normally look. We see no structural tailwind in the figures provided and no identifiable near-term catalyst that would reverse the revenue decline. A deeper look would only be worth the time if a specific restructuring, asset sale or refinancing were already underway, and nothing in the data here points to one.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | $0.05 | $0.07 | $0.05 |
| 21 Oct 2026, 01:52 CEST | ACCE price target | $0.07 | $0.09 | $0.07 |
| 20 Oct 2026, 02:20 CEST | ACCE price target | $0.09 | $0.05 | $0.11 |
| 15 Oct 2026, 00:00 CEST | ACCE price target | $0.05 | first publication | $0.08 |
| 29 Aug 2026, 00:00 CEST | Fair value | $6.17 | $6.40 | $3.50 |
| 26 Aug 2026, 00:00 CEST | Fair value | $6.40 | $6.75 | $3.77 |
| 23 Aug 2026, 00:00 CEST | Fair value | $6.75 | $7.20 | $4.13 |
| 21 Aug 2026, 00:00 CEST | Fair value | $7.20 | $0.44 | $4.67 |
| 17 Jul 2026, 00:00 CEST | Fair value | $0.44 | $0.52 | $2.52 |
| 10 Jul 2026, 00:00 CEST | Fair value | $0.52 | first publication | $2.54 |
Answered from China SXT Pharmaceuticals Inc. Class A Ordinary Shares fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| SXTC China SXT Pharmaceuticals Inc. Class A Ordinary Shares | $0.04 | - | - | - | -27.5% | 35 | 36 |
| RICH.BA Laboratorios Richmond SACIF | ARS 1365.00 | - | - | 7.7x | 13.2% | 53 | 47 |
| LABB.MX Genomma Lab Internacional | MXN 14.68 | MXN 21 | 29% below | 8.6x | 14.2% | 76 | 55 |
| BIOG-B.ST BioGaia AB (publ) | kr 129.30 | kr 74 | 76% above | 34.3x | 30.8% | 100 | 68 |
| AJANTPHARM.NS Ajanta Pharma Limited | ₹3270.60 | - | - | 36.2x | - | 96 | 74 |
| IPCALAB.NS Ipca Laboratories Limited | ₹1903.50 | - | - | 36.9x | - | 91 | 78 |
| 4506.T Sumitomo Pharma Co., Ltd. | ¥1904.00 | - | - | 7.6x | 38.5% | 84 | 73 |
Where SXTC ranks against its sector peers on each metric.